SpringerLink
Log in

Pre-menopausal breast cancer and aromatase inhibitors: treating a new generation of women

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Aromatase inhibitors have revolutionized the treatment of post-menopausal women with hormone receptor positive breast cancer. However, approximately 22% of all cases of breast cancer in North America are diagnosed in women below the age of 50 and a substantial proportion of these women are pre-menopausal. In the pre-menopausal population with hormone receptor positive disease, research on the use of aromatase inhibitors is only beginning to emerge. In this review, the mechanism of action of aromatase inhibitors and the history of endocrine treatment for pre-menopausal breast cancer is briefly presented. Available research to date regarding efficacy and toxicity of aromatase inhibitors in the treatment of pre-menopausal breast cancer and future research directions are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aebi S, Castiglione-Gertsch M (2003) Adjuvant endocrine therapy for the very young patients. Breast 12:509–515

    Article  PubMed  Google Scholar 

  2. Clemons M, Coleman RE, Verma S (2004) Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? Cancer Treat Rev 30(4):325–332

    Article  PubMed  CAS  Google Scholar 

  3. Freedman OC, Verma S, Clemons MJ (2005) Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? Cancer Treat Rev 31(1):1–17

    Article  PubMed  CAS  Google Scholar 

  4. Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. New Engl J Med 344(4):276–285

    Article  PubMed  CAS  Google Scholar 

  5. Judd HL (1976) Hormonal dynamics associated with menopause. Clin Obstet Gynecol 19(4):775–788

    Article  PubMed  CAS  Google Scholar 

  6. Dowsett M, Haynes BP (2003) Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol 86:255–263

    Article  PubMed  CAS  Google Scholar 

  7. Goss PE, Strasser K (2001) Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19(3):881–894

    PubMed  CAS  Google Scholar 

  8. Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A (2005) Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 23:1736–1750

    Article  PubMed  CAS  Google Scholar 

  9. Wander HE, Blossey HC, Nagel GA (1986) Aminoglutethamide in the treatment of premenopausal patients with metastatic breast cancer. Eur J Clin Oncol 22(11):1371–1374

    Article  CAS  Google Scholar 

  10. Bezwada WR, Dansey RD, Hesdorffer CS, Browde S (1987) Use of aminoglutethamide for the treatment of advanced breast cancer: clinical correlations with previous treatment, oestrogen-receptor, and menstrual status. SAMT 72(18):107–109

    Google Scholar 

  11. Stein RC et’al (1990) The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 62:679–683

    PubMed  CAS  Google Scholar 

  12. Celio L, Martinetti A, Ferrari L (1999) Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res 19 (3B):2261–68

    Google Scholar 

  13. Dowsett M et’al (1999) Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 56:25–34

    Article  PubMed  CAS  Google Scholar 

  14. Forward DP, Cheung KL, Jackson L, Robertson JFR (2004) Clinical and endocrine data for goserelin plus anastrazole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90:590–594

    Article  PubMed  CAS  Google Scholar 

  15. Carlson RW et’al (2004) Goserelin plus anastrazole for the treatment of premenopausal women with hormone receptor positive, recurrent/metastatic breast cancer. Breast Cancer Res Treat 88(suppl 1):237S [abst 6052]

    Google Scholar 

  16. Cheung K, Winterbottom L, Owers R, Robertson J (2005) Goserelin plus anastrazole as first-line endocrine therapy for premenopausal women with estrogen receptor (ER) positive advanced breast cancer (ABC). J Clin Oncol 23(16S):60S [abst 731]

    Google Scholar 

  17. Martinetti A et’al (2000) The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers. J Steroid Biochem Mol Biol 75(1):65–73

    Article  PubMed  CAS  Google Scholar 

  18. Dowsett M, Haynes BP (2003) Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol 86:255–263

    Article  PubMed  CAS  Google Scholar 

  19. Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. New Engl J Med 348(24):2431–2442

    Article  PubMed  CAS  Google Scholar 

  20. Baum M et’al (2002) Anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 359:2131–2139

    Article  PubMed  CAS  Google Scholar 

  21. Coleman RE (2004) Effect of anastrazole on bone mineral density and bone fractures: results from the ȁ8arimidexȁ9 (anastrazole), tamoxifen, alone or in combination (ATAC) trial. Eur J Cancer 2(suppl 3):140

    Google Scholar 

  22. Goss PE et’al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New Engl J Med 349(19):1793–1802

    Article  PubMed  CAS  Google Scholar 

  23. The BIG International Study Group (2005) A comparison of letrozole and tamoxifen in premenopausal women with early breast cancer. New Engl J Med 353(26):2747–2757

    Article  Google Scholar 

  24. Coombes RC et’al on behalf of the Intergroup Exemestane Study (IES) (2004) Exemestane improves disease-free survival in postmenopausal patients with early breast cancer after two to three years of tamoxifen: a double blind randomized trial. New Engl J Med 350(11):1081–1092

    Google Scholar 

  25. Perez EA, Josse RG, Pritchard KI, Ingle JN (2004). Effect of letrozole versus placebo on bone mineral density in women completing >5 years of adjuvant tamoxifen. Breast Cancer Res Treat 88(suppl 1):S36 [abs 404]

    Google Scholar 

  26. Coleman RE, Banks LM, Hall E et’al (2004) Intergroup exemestane study: 1 year results of the bone sub-protocol. Breast Cancer Res Treat 88(suppl 1):S35 [abs 402]

  27. Martinetti A et’al (2000) The luteinizing hormone releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on␣bone metabolism markers. J Steroid Biochem Mol Biol 75:65–73

    Article  PubMed  CAS  Google Scholar 

  28. Gnant M et’al (2002) Changes in bone mineral density caused by anastrazole or tamoxifen in combination with goserelin (+/− zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: results of a radndomized multicenter trial. Breast Cancer Res Treat 76(suppl 1):abstr 12

  29. Sawada S, Sato K (2003) Effect of anastrazole and tamoxifen on serum lipid levels in Japanese postmenopausal women with early breast cancer. Breast Cancer Res Treat 83(suppl 1):S31 [abst 143]

    Google Scholar 

  30. Markopolous C et’al (2003) The effect of exemestane (Aromasin) on the lipidemic profile of breast cancer patients: preliminary results of the TEAM trial Greek sub-study. Breast Cancer Res Treat 83(suppl 1):S105 [abst 440]

    Google Scholar 

  31. Coombes RC, Bliss JM, Hall E (2005) Safety of Exemestane in the Intergroup Exemestane Study. J Clin Oncol 23(13):3171–3172

    Article  PubMed  Google Scholar 

  32. Bergman L et’al (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centresȁ9 ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356(9233):881–887

    Article  PubMed  CAS  Google Scholar 

  33. Duffy SR, Greenwood M (2003) The endometrial cancer data from the ATAC (arimidex, tamoxifen, alone or in combination) trial indicates a protective effect of anastrazole (arimidex) upon the endometrium. Breast Cancer Res Treat 83(suppl 1):S29 [abst 134]

    Google Scholar 

  34. Tchen N, Juffs HG, Downie FP, Yi QL, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D, Tweedale ME, Tannock IF (2003) Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21(22):4175–4183

    Article  PubMed  Google Scholar 

  35. Bender CM et’al (2005) Memory impairments with anastrozole versus tamoxifen therapy in women with early stage breast cancer. SABCS [abst. 6074]

  36. Goldhirsh A et’al (2001) Adjuvant therapy for very young women with breast cancer: need for tailored treatments. JNCI Monographs 30:44–51

    Google Scholar 

  37. Braverman AS, Sawhney H, Tendler A, Patel N Rao S (2002) Premenopausal serum estradiol (E2) levels may persist after chemotherapy (CT)-induced amenorrhea in breast cancer (BC). Proc Am Soc Clin Oncol 21:42A [abst.164]

    Google Scholar 

  38. Osborne CK, Bardou V, Hopp TA et’al (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353–361

    Article  PubMed  CAS  Google Scholar 

  39. Knoop AS, Bentzen SM, Nielsen MM et’al (2001) Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19:3376–3384

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, M4N 3M5, Toronto, Ontario, Canada

    O.C. Freedman, S. Verma & M.J. Clemons

Authors
  1. O.C. Freedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Verma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M.J. Clemons
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M.J. Clemons.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Freedman, O., Verma, S. & Clemons, M. Pre-menopausal breast cancer and aromatase inhibitors: treating a new generation of women . Breast Cancer Res Treat 99, 241–247 (2006). https://doi.org/10.1007/s10549-006-9208-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-006-9208-x

Keywords

Search

Navigation